Skip to main content
Advertisement
Advertisement

HRTX

HRTX logo

Heron Therapeutics, Inc.

0.29
USD
Sponsored
0.00
+1.45%
Sep 25, 15:59 UTC -4
Closed
exchange

After-Market

0.29

0.00
-1.43%

HRTX Earnings Reports

Positive Surprise Ratio

HRTX beat 21 of 42 last estimates.

50%

Next Report

Date of Next Report
Nov 02, 2026
Estimate for Q3 26 (Revenue/ EPS)
$38.25M
/
-$0.02
Implied change from Q2 26 (Revenue/ EPS)
+1.55%
/
-33.33%
Implied change from Q3 25 (Revenue/ EPS)
+0.10%
/
-50.00%

Heron Therapeutics, Inc. earnings per share and revenue

On Aug 10, 2026, HRTX reported earnings of -0.03 USD per share (EPS) for Q2 26, missing the estimate of 0.01 USD, resulting in a -394.12% surprise. Revenue reached 37.67 million, compared to an expected 43.04 million, with a -12.49% difference. The market reacted with a -31.74% price change (close before vs. close after earnings).
Looking ahead to Q3 26, -- analysts forecast an EPS of -0.02 USD, with revenue projected to reach 38.25 million USD, implying an decrease of -33.33% EPS, and increase of 1.55% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
PharmaCyte Biotech, Inc. Common Stock
Report Date
Sep 14, 2026 For Q1 27
Estimate
-
Actual
-$0.54
Surprise
-
FAQ
For Q2 2026, Heron Therapeutics, Inc. reported EPS of -$0.03, missing estimates by -394.12%, and revenue of $37.67M, -12.49% below expectations.
The stock price moved down -31.74%, changed from $0.49 before the earnings release to $0.34 the day after.
The next earning report is scheduled for Nov 02, 2026.
Based on -- analysts, Heron Therapeutics, Inc. is expected to report EPS of -$0.02 and revenue of $38.25M for Q3 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement